tiprankstipranks
Advertisement
Advertisement

ORIC Stock Latest News

Oric Shareholders Approve Equity Plan, Governance Measures
Company AnnouncementsOric Shareholders Approve Equity Plan, Governance Measures
18d ago
8K
ORIC
Oric Pharmaceuticals resumed with a Buy at Stifel
PremiumThe Fly
Oric Pharmaceuticals resumed with a Buy at Stifel
29d ago
ORIC
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained
1M ago
ORIC
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
PremiumRatings
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
2M ago
ORIC
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
PremiumThe Fly
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
2M ago
ORIC
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
PremiumRatingsORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
2M ago
ORIC
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
Premium
The Fly
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
2M ago
ORIC
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
Premium
The Fly
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
2M ago
ORIC
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
PremiumThe Fly
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
3M ago
ORIC
3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts
3M ago
ENGN
ORIC
Oric selloff brings attractive entry point, says H.C. Wainwright
PremiumThe Fly
Oric selloff brings attractive entry point, says H.C. Wainwright
3M ago
ORIC
Oric Pharmaceuticals should be bought on selloff, says Citi
PremiumThe Fly
Oric Pharmaceuticals should be bought on selloff, says Citi
3M ago
ORIC
Midday Fly By: Nike falls after earnings, Conagra reports mixed results
PremiumThe FlyMidday Fly By: Nike falls after earnings, Conagra reports mixed results
3M ago
LW
RH
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
Premium
The Fly
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
3M ago
PFE
ORIC
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
Premium
The Fly
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
3M ago
PFE
ORIC
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
PremiumThe Fly
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
3M ago
ORIC
Video: Nike stumbles as timeline for recovery pushed out
PremiumThe Fly
Video: Nike stumbles as timeline for recovery pushed out
3M ago
RH
TH
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
PremiumCompany Announcements
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
3M ago
8K
ORIC
Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
PremiumThe Fly
Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
3M ago
RH
NKE
Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update
PremiumThe FlyOric Pharmaceuticals announces rinzimetostat, ORIC-944, program update
3M ago
ORIC
Oric selloff brings favorable entry point, says H.C. Wainwright
Premium
The Fly
Oric selloff brings favorable entry point, says H.C. Wainwright
4M ago
ORIC
Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year
Premium
The Fly
Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year
4M ago
ORIC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >